Abstract | OBJECTIVE: DESIGN: A prospective nonrandomized controlled trial. SETTING: A primary care and referral university hospital center. PATIENTS: All patients scheduled for parotidectomy from April 1994 through August 1998 were eligible. Seventy patients were enrolled (2 refused). All 70 patients were evaluated for wound complications. Sixty patients with a follow-up of more than 1 year were evaluated for Frey syndrome. INTERVENTION: OUTCOME MEASURES: The incidence of Frey syndrome was evaluated (1) subjectively by history (clinical Frey syndrome) and (2) objectively by using 2 newly developed tests. Both hemifaces were tested, with the normal side being used as a control. RESULTS: Clinical Frey syndrome was present in 12 patients: 11 without implants (11/24 [53%]) and 1 with an implant (1/46 [2%]) (P<.001). Objective tests were positive in 24 patients: 16 (76%) of 21 without implants and 8 (20%) of 39 with implants (P<.001). In the implanted patients, the objective tests were positive in 71% (5/7) of those with lyophilized dura, 14% (1/7) of those with Ethisorb, and 8% (2/29) of those with e- PTFE implants (P<.001). Wound complications included hematoma in 5 patients (7%), seroma in 4 patients (6%), and salivary fistula in 15 (21%). Salivary fistula occurred more frequently with Ethisorb (57%) and e- PTFE (25%) implants (P = .04). CONCLUSIONS: In patients without an implant, the incidence of Frey syndrome is 50% for subjective and 80% for objective evaluation. In patients with an implant, these incidences are 3% and 10%, respectively. Some implants are associated with a higher incidence of salivary fistula.
|
Authors | P Dulguerov, D Quinodoz, G Cosendai, P Piletta, F Marchal, W Lehmann |
Journal | Archives of otolaryngology--head & neck surgery
(Arch Otolaryngol Head Neck Surg)
Vol. 125
Issue 8
Pg. 833-9
(Aug 1999)
ISSN: 0886-4470 [Print] United States |
PMID | 10448728
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Polydioxanone
- Polyglactin 910
- Polytetrafluoroethylene
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Bone and Bones
- Child
- Desiccation
- Female
- Humans
- Incidence
- Male
- Middle Aged
- Parotid Gland
(surgery)
- Polydioxanone
(therapeutic use)
- Polyglactin 910
(therapeutic use)
- Polytetrafluoroethylene
(therapeutic use)
- Postoperative Complications
- Prospective Studies
- Prostheses and Implants
- Surgical Mesh
- Sweating, Gustatory
(prevention & control, surgery)
|